No Data
No Data
No Data
No Data
No Data
A watershed in ADC track investment has emerged, and “false competition+hematopoietic research and development” has become a new weather vane?
In particular, at a time when market expectations of the Federal Reserve's interest rate cut have declined sharply, and the global biomedical financing environment is far from improving, investors are more willing to look at companies with greater certainty.
Zhitong FinanceApr 26 04:18 ET
Top Gap Ups and Downs on Thursday: META, AZN, CAT and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsApr 25 20:13 ET
Top Gap Ups and Downs on Wednesday: TSLA, TXN, BSX and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsApr 24 19:42 ET
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)
TipRanksApr 16 20:21 ET
J&J Sets Guidance Below Consensus as MedTech Underperforms
Seeking AlphaApr 16 07:20 ET
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug
Genmab (GMAB.CO) on Tuesday said the net sales for its multiple myeloma drug Darzalex rose year over year in the first quarter ended March. Net sales of Darzalex amounted to $2.69 billion in the first
MT NewswiresApr 16 07:19 ET
No Data
No Data